ZipCode Bio
Private Company
Total funding raised: $4M
Overview
Founded in 2019, ZipCode Bio is a private, early-stage biotech focused on the intersection of genetics, diagnostics, and advanced technologies like A.I. and delivery systems. The company's strategy is centered on building partnerships to co-develop its platform, which targets personalized medicine applications. Based on its website and limited public data, it is likely in a pre-revenue, platform-building stage, with its specific pipeline programs and leadership team not publicly disclosed. The company's success will hinge on validating its technological approach and securing strategic collaborations.
Technology Platform
Integrated platform combining Artificial Intelligence (A.I.) for genetic data analysis with novel extra-hepatic delivery technologies for targeted genetic medicine applications.
Funding History
1Opportunities
Risk Factors
Competitive Landscape
ZipCode Bio competes in two crowded and cutting-edge fields: AI/ML for genomics (e.g., Tempus, Sophia Genetics) and novel delivery platforms for genetic medicines (e.g., Dyno Therapeutics, Ring Therapeutics, many large biopharma internal efforts). Its differentiation hinges on uniquely combining these capabilities and demonstrating superior efficacy.